Jaguar Health (JAGX) Cash & Equivalents (2014 - 2026)

Jaguar Health (JAGX) has 13 years of Cash & Equivalents data on file, last reported at $7.3 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 27.91% year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a 27.91% increase from a year earlier, with the FY2025 full-year figure at $968000.0, down 87.9% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.3 million, up from $968000.0 in the prior quarter.
• Over the last five years, Cash & Equivalents for JAGX reached as high as $17.5 million in Q1 2022 and fell as low as $968000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $8.5 million across 5 years, with a median of $8.0 million in 2024.
• Across the five-year window, Cash & Equivalents surged 311.31% in 2024 and tumbled 87.9% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $5.5 million in 2022, then grew by 18.28% to $6.5 million in 2023, then advanced by 23.7% to $8.0 million in 2024, then tumbled by 87.9% to $968000.0 in 2025, then soared by 651.86% to $7.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.3 million in Q1 2026, $968000.0 in Q4 2025, and $3.5 million in Q3 2025.